Phase 2 Lymphoma Trial, Recruiting NCT06314334 Sponsor: Fudan University Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06314334
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a type of lymphoma called NK/T-cell lymphoma (NKTCL), confirmed by a tissue biopsy.
  • Your lymphoma started in the upper part of the airway or digestive tract, such as the nasal cavity, sinuses, back of the throat, or mouth, and is at an early stage (Stage IE or IIE) based on scans and bone marrow tests.
  • You have at least one area of lymphoma that can be measured or seen on a PET/CT scan.
  • You have never previously received chemotherapy, radiotherapy, immunotherapy, or any other cancer treatment for this lymphoma.
  • You are between 18 and 75 years old.
  • You are generally able to carry out daily activities, with only mild limitations at most (confirm with trial site).
  • Your blood counts, liver, kidneys, clotting, and heart function all meet certain minimum health levels as measured by blood tests and a heart scan (confirm with trial site for specific values).
  • You are willing and able to follow the study schedule, including all required visits and tests.

Who may not be able to join:

  • You are infected with Hepatitis C (HCV), HIV, or have Hepatitis B (HBV) with a high level of the virus in your blood.
  • You have a history of pancreatitis (inflammation of the pancreas).
  • You currently have a serious infection that requires antibiotic treatment given through a drip (intravenously).
  • You have serious complications such as hemophagocytic syndrome or DIC (conditions affecting the blood and immune system) (confirm with trial site).
  • You have significant problems with major organs, such as breathing failure, moderate-to-severe heart failure, poorly controlled liver or kidney disease, uncontrolled high blood pressure or diabetes, or a blood clot or serious bleeding event in the past 6 months.
  • You have a history of an autoimmune disease that makes immune-based treatments unsuitable for you (confirm with trial site).
  • You are currently pregnant or breastfeeding.
  • You have a diagnosed psychiatric (mental health) disorder.
  • You have a known allergy to any of the drugs used in the chemotherapy treatment plan for this trial.
  • You have had another cancer that required surgery or chemotherapy within the past 6 months.
  • You are currently taking part in another clinical trial or using another experimental drug.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Rong Tao, MD, Fudan Cancer Hospital

Phone: 8621-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 March 2024
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS24

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov